enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. RNAi nanoparticles to target cancer - Wikipedia

    en.wikipedia.org/wiki/RNAi_nanoparticles_to...

    Multidrug resistance in cancer cells is thought to be the primary reason for the poor efficacy of cancer chemotherapy. Drug resistance is due to expression of the gene MDR-1. These gene codes for membrane-bound proteins called ABC transporters. One example of an ABC transporter is P-glycoprotein (P-gp).

  3. CRISPR gene editing - Wikipedia

    en.wikipedia.org/wiki/CRISPR_gene_editing

    In July 2018, the ECJ ruled that gene editing for plants was a sub-category of GMO foods and therefore that the CRISPR technique would henceforth be regulated in the European Union by their rules and regulations for GMOs. [37] In February 2020, a US trial showed safe CRISPR gene editing on three cancer patients. [38]

  4. New Gene-Editing Treatments, Explained - AOL

    www.aol.com/news/gene-editing-treatments...

    For premium support please call: 800-290-4726 more ways to reach us

  5. Intellia Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Intellia_Therapeutics

    Intellia also has a number of research programs for in vivo and ex vivo therapeutic candidates with potential applications in diseases including cancer, alpha-1 antitrypsin deficiency, and hemophilia. The company is also working on a variety of additional gene editing technologies including base editing and DNA writing. [5] [6]

  6. FDA considers first CRISPR gene editing treatment that may ...

    www.aol.com/fda-considers-first-crispr-gene...

    In company studies, the treatment was considered safe, and it had a “highly positive benefit-risk for patients with severe sickle cell disease,” Dr. Stephanie Krogmeier, vice president for ...

  7. Oncolytic adenovirus - Wikipedia

    en.wikipedia.org/wiki/Oncolytic_adenovirus

    A suitable tumour-specific promoter for prostate cancer is prostate-specific antigen (PSA), whose expression is greatly elevated in prostate cancer. CN706 is a CRAd with a PSA tumour-specific promoter driving expression of the adenoviral E1A gene, required for viral replication. The CN706 titre is significantly greater in PSA-positive cells. [10]

  8. FDA approves two gene therapies for sickle cell, bringing ...

    www.aol.com/news/fda-expected-approve-first...

    The US Food and Drug Administration on Friday approved two gene-based treatments for sickle cell disease, including the first therapy that uses the gene-editing technique CRISPR, opening a new era ...

  9. Glutamate carboxypeptidase II - Wikipedia

    en.wikipedia.org/wiki/Glutamate_carboxypeptidase_II

    This new technology was approved by the FDA on Dec 1, 2020. [30] A dual-modality small molecule that is positron-emitting (18 F) and fluorescent targets PSMA and was tested in humans. The molecule found the location of primary and metastatic prostate cancer by PET, fluorescence-guided removal of cancer, and detects single cancer cells in tissue ...